RecruitingPHASE1, PHASE2NCT02830724
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Studying Malignant germ cell tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- James C Yang, M.D.National Cancer Institute (NCI)
- Intervention
- Cyclophosphamide(drug)
- Enrollment
- 124 enrolled
- Eligibility
- 18-72 years · All sexes
- Timeline
- 2017 – 2028
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02830724 on ClinicalTrials.govOther trials for Malignant germ cell tumor of ovary
Additional recruiting or active studies for the same condition.